

Shaping the future  
of science

# THRPTX

THERAPEUTICS  
INNOVATION SUMMIT



**SERVIER**  
moved by you

**SERVIER**  
moved by you

# The forum for scientific excellence and therapeutic innovations of tomorrow



## EXCLUSIVE EVENT

Organized by Servier Group, a major player in Oncology, this “by invitation only” event will be held on **June 18, 2024** at the new Servier Paris-Saclay R&D Institute in France.

---

## PANEL OF LEADING INTERNATIONAL SCIENTIFIC EXPERTS

The half-day event will feature leading international scientific experts, under the patronage of **Prof. William G. Kaelin Jr**, Professor of Medicine at Harvard University and recipient of the 2019 Nobel Prize in Medicine.

---

## CATALYST FOR SCIENTIFIC EXCELLENCE

The event will bring together **200 scientific experts**, decision-makers, and healthcare professionals to share their thoughts on therapeutic innovation, its impact on society, and the emergence of new developments expected to accelerate therapeutic research.

# An international scientific summit to collectively reflect on major therapeutic advances in oncology

**JUNE 18TH, 2024 - FROM 2.00PM TO 6.00PM - AT SERVIER PARIS-SACLAY R&D INSTITUTE**

1:30-2:00: **WELCOME COFFEE - REGISTRATION**

2:00-2:45: OPENING KEYNOTE BY **PROFESSOR WILLIAM G. KAELIN JR, 2019 NOBEL LAUREATE IN PHYSIOLOGY AND MEDICINE**

2:45-4:00: **A FIRST SESSION** with leading international experts in oncology to discuss on how therapeutic innovation provides solutions to cancer patients with:

- **Hsin-An Hou**, Hematologist at National Taiwan University Hospital
- **Susan Pandya**, Vice President Clinical Development, Global Head of Cancer Metabolism at Servier
- **Hans Scheurer**, PhD, CEO at Myeloma Patients Europe and Vice-chair at European Cancer Patient Advocacy Networks
- **Ines Vaz-Luis**, MD, Medical oncologist at Gustave Roussy and instructor in Medicine at Harvard University
- **Andrew Wei**, MBBS, PhD, co-leads the acute myeloid leukemia program at the Peter MacCallum Cancer Center and Royal Melbourne Hospital in Melbourne, Australia

4:00-4:30: **COFFEE BREAK**

4:30-5:30: **A SECOND SESSION** with high profile speakers to discuss on how society copes with breakthrough therapeutic innovation with:

- **Sandrine Bourguignon**, Professor health economist at Paris Dauphine-PSL & RWEality co-founder & CEO
- **David Edwards**, PhD, Harvard University, Associate in Bioengineering and founder of the World Frontiers Forum think tank
- **Dipak Kalra**, MB BS, President of the European Institute for Innovation Through Health Data
- **Hugues de Thé**, MD, PhD, Professor at the Collège de France, holder of the Chair in Cellular and Molecular Oncology, member of the Academy of Science

Panels moderated by **Ariane Warlin**

5:30-6:00: **FIRESIDE CHAT, A WRAP-UP DISCUSSION** between Prof. William G. Kaelin and a member of the Servier post-doctoral community.

**Possibility to visit** the research facilities and to network with guests and speakers

**LOCATION OF THE EVENT:** Servier R&D Institute at Paris-Saclay: 22, route 128 - 91190 Gif sur Yvette - FRANCE



# Servier, founded to serve health and patients

**MORE THAN 20%**  
of the revenue from brand-name medicines is invested in R&D

## SERVIER IS COMMITTED TO THERAPEUTIC PROGRESS TO SERVE PATIENT NEEDS

- An independent Group, **governed by a foundation**
- A world leader in **cardiometabolic** and **venous diseases**
- An industry innovator in **oncology**, neuroscience, and immuno-inflammation

**62 R&D PROJECTS IN PROGRESS\***  
\*December 2023

## SIGNIFICANT SOCIAL IMPACT FOR PATIENTS

- Over **20% of the Group's revenue** from brand-name medicines is invested each year in R&D, **70% of which is dedicated to oncology**
- **A promising pipeline of 62 projects**, including 36 in development and 26 in research\* (half of which are in oncology)

**MORE THAN 70**  
partnerships and collaborations

## GLOBAL REACH, WITH STRONG HISTORICAL ROOTS IN FRANCE

- **4.9 billion euros** in revenues (2021-2022)
- **2nd leading pharmaceutical group in France**
- 97% of active ingredients for the Group's brand-name medicines produced in France
- **59% of Group investments** made in **France**
- **More than 70 scientific partnerships** and collaborations worldwide
- **4 R&D centers** worldwide (Paris-Saclay - France, Boston - USA, Budapest - Hungary, Ballerup - Denmark)
- **15 offices** worldwide to coordinate clinical development

**4 R&D centers**  
worldwide



# Scientific excellence at the heart of the Paris-Saclay global innovation hub



## PARIS-SACLAY, A WORLD-CLASS RESEARCH AND DEVELOPMENT HUB

concentrating **15% of French R&D**.

## EXCEPTIONAL ENVIRONMENT

Designed to foster the exchange and sharing of know-how, this exceptional setting provides the ideal conditions for shaping the **innovations of tomorrow**.

## UNIQUE ECOSYSTEM

**One of the world's top eight innovation clusters,** Paris-Saclay is ideally poised to forge new partnerships and collaborations with institutional and private research stakeholders such as *CNRS, CEA, École Polytechnique, the Faculty of Pharmacy, and the University of Paris-Saclay*, which is listed in Shanghai Academic Ranking 2023's Top 20<sup>1</sup>.

ACCOUNTS  
FOR 15%  
OF FRENCH  
R&D

AMONG TOP 8  
INNOVATION  
HUBS  
WORLDWIDE